Insulin aspart

Generic Name
Insulin aspart
Brand Names
Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
Drug Type
Biotech
Chemical Formula
-
CAS Number
116094-23-6
Unique Ingredient Identifier
D933668QVX
Background

Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.

Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin aspart, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as Metformin, Gliclazide, or Sitagliptin have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.

Marketed as the brand name product NovoRapid, insulin aspart begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, NovoRapid is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as Insulin detemir, Insulin degludec, and Insulin glargine to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.

Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. Compared to human insulin, it has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Insulin aspart is produced in a genetically modified strain of Saccharomyces cerevisiae (baker's yeast)

Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.

Indication

Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.

Associated Conditions
Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
Associated Therapies
-

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

First Posted Date
2012-02-06
Last Posted Date
2019-02-26
Lead Sponsor
Halozyme Therapeutics
Target Recruit Count
25
Registration Number
NCT01526733
Locations
🇺🇸

Profil Institute for Clinical Research, Chula Vista, California, United States

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

First Posted Date
2012-01-30
Last Posted Date
2017-01-04
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
35
Registration Number
NCT01520831
Locations
🇩🇪

Novo Nordisk Investigational Site, Neuss, Germany

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

First Posted Date
2012-01-20
Last Posted Date
2019-06-13
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
350
Registration Number
NCT01513473
Locations
🇬🇧

Novo Nordisk Investigational Site, Sheffield, United Kingdom

Surveillance Study of NovoRapid® for New Drug Re-examination

First Posted Date
2011-12-12
Last Posted Date
2016-10-28
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
1239
Registration Number
NCT01490112
Locations
🇰🇷

Novo Nordisk Investigational Site, Seoul, Korea, Republic of

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

First Posted Date
2011-12-07
Last Posted Date
2017-01-27
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
598
Registration Number
NCT01486940
Locations
🇸🇪

Novo Nordisk Investigational Site, Falun, Sweden

Special Survey for Paediatric Subjects

First Posted Date
2011-12-07
Last Posted Date
2016-03-04
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
241
Registration Number
NCT01487382

Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

First Posted Date
2011-12-07
Last Posted Date
2017-03-17
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
58
Registration Number
NCT01486966
Locations
🇨🇳

Novo Nordisk Investigational Site, Shanghai, Shanghai, China

An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

First Posted Date
2011-12-07
Last Posted Date
2014-06-24
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
2134
Registration Number
NCT01487421

Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-12-07
Last Posted Date
2017-03-01
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
28
Registration Number
NCT01486914
Locations
🇬🇧

Novo Nordisk Investigational Site, Manchester, United Kingdom

Special Survey for Type 1 or Type 2 Diabetic Patients

First Posted Date
2011-12-07
Last Posted Date
2016-03-04
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
1463
Registration Number
NCT01487408
© Copyright 2024. All Rights Reserved by MedPath